ImmunoPrecise Antibodies Ltd. Files Form 6-K
Ticker: HYFT · Form: 6-K · Filed: Oct 28, 2024 · CIK: 1715925
Sentiment: neutral
Topics: reporting, foreign-private-issuer, press-release
TL;DR
IPA files 6-K on Oct 28, 2024, with press release. Standard reporting update.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 28, 2024, to report a press release dated October 28, 2024. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing serves as an official notification to the SEC and investors about the company's reporting status and includes a press release, which may contain important operational or strategic updates.
Risk Assessment
Risk Level: low — This is a routine filing that primarily serves to submit a press release and confirm reporting status, with no immediate financial or operational disclosures that would indicate high risk.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- October 28, 2024 (date) — Date of the press release and filing
- Kristin Taylor (person) — Signatory for the company
- 001-39530 (other) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It is used to furnish information that the company may be required to make public in its home country, file with a stock exchange, or distribute to its security holders.
What specific exhibit is included with this Form 6-K?
This Form 6-K includes Exhibit 99.1, which is a Press Release dated October 28, 2024.
What is ImmunoPrecise Antibodies Ltd.'s principal executive office address?
ImmunoPrecise Antibodies Ltd.'s principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Does ImmunoPrecise Antibodies Ltd. file annual reports under Form 20-F or 40-F?
ImmunoPrecise Antibodies Ltd. indicates it files annual reports under cover of Form 20-F.
Who signed this Form 6-K on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor signed this Form 6-K on behalf of ImmunoPrecise Antibodies Ltd., as indicated by the signature /s/ Kristin Taylor.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-10-28 07:36:23
Filing Documents
- press_release_oct_28_202.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 18KB
- 0000950170-24-117572.txt ( ) — 40KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: October 28, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer